Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
|Poll|February 23, 2018
Mini Quiz: Deep Brain Stimulation for Memory Impairment
Author(s)Darrin J. Lee, MD, PhD
Which brain regions are potential deep brain stimulation targets for neurological disorders with memory impairment? Take the quiz and learn more.
Advertisement
Which part of the brain is NOT a potential deep brain stimulation target for neurological disorders with memory impairment?
Advertisement
Related to this article
Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.
In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.
A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
2
Advances in Spinal Cord MRI for Multiple Sclerosis: Julien Cohen-Adad, PhD
3
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
4
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
5